Student’s Attitudes toward Academic Dishonesty: An Exploration

Academic dishonesty in college/university classrooms is widely recognized as a serious problem (Offstein and Chory 2017). Studies indicate that academic dishonesty is pervasive. Klein, Levenburg, McKendall, and Mothersell (2007), report 40-80 percent of college students are involved in academic dishonesty, whereas McCabe, Butterfield, and Treviňo (2012), report 65-87 percent involvement. Studies also report that cheating activity is increasing (Forsha 2017; Pérez-Peňa 2012), facilitated by increasing levels of tolerance (where instances of academic dishonesty are overlooked by classroom instructors (Coren 2011)), and advances in technology (Best and Shirley 2018). Consequently, academic dishonesty has become an increasingly important area of concern and, likewise, an important area of study (Robinson and Glanzer 2017). Academic dishonesty is not a victimless activity. With the growth of cheating activity, the integrity of higher education is increasingly being questioned (Drye, Lomo-David, and Snyder 2018). Pervasive academic dishonesty prevents academic institutions from being able to certify that graduates have gained a specific level of knowledge and ability from their education (Yu, Glanzer, Johnson, Sriram, and Moore 2018). Academic dishonesty has also been connected with a number of other undesirable activities (Biswas 2014), including unethical work behaviors (Harding, Carpenter, Finelli, and Passow 2004). Several studies suggest that academic dishonesty primes students for continuing dishonesty in their subsequent employment (e.g., Harding, Carpenter, Finelli, and Passow 2004; Hsiao and Yang 2011; Nonis and Swift 2001; Yang, Huang, and Chen 2013). Consequently, recent highly publicized business scandals have focused renewed attention on cheating activities in the classroom (Rakovski and Levy 2007). Past ethics research has explored many important issues involving academic dishonesty, including the effectiveness of various tactics to reduce the incidence of academic dishonesty. Examples of these tactics include the implementation/enforcement of honor codes (McCabe, Treviño, and Butterfield 2001; Tatum and Schwartz 2017), required ethics courses (Medeiros et al. 2017), ethics instruction integrated into discipline-specific coursework (Desplaces, Melchar, Beauvais, and Bosco 2007), campus climate (Molar 2015), and the activities of faculty to fight dishonesty (Coalter, Lim, and Wanorie 2007). The attitudes of students toward academic dishonesty have also received a significant amount of research attention (e.g., Johns and Strand 2007). An area that has not received the same level of research attention involves the effects that students’ perceptions of the ethicality of their academic environment have on their attitudes toward academic dishonesty. Specifically, do students’ perceptions of the ethicality of their college/university, their faculty, and their student body affect their attitudes toward academic dishonesty? This is an important area of study since if students’ attitudes toward academic dishonesty are affected by their perceptions of the ethicality of their institution and their colleagues, it may be possible to affect students’ participation in academic dishonesty by affecting their perceptions of their school environment. To explore this issue, first, student academic dishonesty in higher education is examined. Second, hypotheses are developed and tested. Finally, conclusions are drawn

The Inmates Are Running the Asylum: The Role of a Consumer Mentality in Higher Education and Exploring How it Can be Overcome

Serving and satisfying customers is often viewed as the primary function of businesses. Consequently, a customer orientation, or a focus on determining customers’ wants and needs and designing and offering products to satisfy them, is a key concept within marketing. Is the importance of a customer orientation also true in higher education? Several believe that it is. The answer to the question of who is the customer in higher education, however, is less clear. Historically, society was viewed to be the primary customer of higher education – the purpose of higher education was viewed to produce educated individuals who possess the knowledge and skills to serve society by serving as leaders in society and its primary institutions, including government and business. Arguably, this view of the purpose of higher educations has changed. Today, students are most often viewed as the customers of higher education. Indeed, when viewing the activities of colleges and universities, the extent to which a consumer mentality has been accepted and employed quickly becomes obvious. The promise of consumer (student) satisfaction is viewed to be key to attracting students and is an essential component of most university marketing programs. Not all agree with this assessment of the role of a consumer mentality in higher education, however. Several believe that a consumer mentality is antithetical to higher education, which logically raises an important question: Why would a customer mentality be appropriate for most organizations, but not higher education? The focus of this special session is to explore this issue

Plate fixation or intramedullary fixation of humeral shaft fractures: An updated meta-analysis

Background The optimal approach to operative treatment of humeral shaft fractures remains debatable. Previously published trials have been limited in size and have been inconclusive regarding important patient outcome variables following treatment with either intramedullary nails or plates. We conducted a meta-analysis of available trials comparing treatment of humeral shaft fractures

Efficacy Results of a Trial of a Herpes Simplex Vaccine

Two previous studies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discordant couples revealed 73% and 74% efficacy against genital disease in women who were negative for both HSV type 1 (HSV-1) and HSV-2 antibodies. Efficacy was not observed in men or HSV-1 seropositive women

Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer:A Randomized Clinical Trial

PURPOSE:Resectable non-small-cell lung cancer (NSCLC) with a high probability of mediastinal nodal involvement requires mediastinal staging by endosonography and, in the absence of nodal metastases, confirmatory mediastinoscopy according to current guidelines. However, randomized data regarding immediate lung tumor resection after systematic endosonography versus additional confirmatory mediastinoscopy before resection are lacking.METHODS:Patients with (suspected) resectable NSCLC and an indication for mediastinal staging after negative systematic endosonography were randomly assigned to immediate lung tumor resection or confirmatory mediastinoscopy followed by tumor resection. The primary outcome in this noninferiority trial (noninferiority margin of 8% that previously showed to not compromise survival, Pnoninferior &lt;.0250) was the presence of unforeseen N2 disease after tumor resection with lymph node dissection. Secondary outcomes were 30-day major morbidity and mortality.RESULTS:Between July 17, 2017, and October 5, 2020, 360 patients were randomly assigned, 178 to immediate lung tumor resection (seven dropouts) and 182 to confirmatory mediastinoscopy first (seven dropouts before and six after mediastinoscopy). Mediastinoscopy detected metastases in 8.0% (14/175; 95% CI, 4.8 to 13.0) of patients. Unforeseen N2 rate after immediate resection (8.8%) was noninferior compared with mediastinoscopy first (7.7%) in both intention-to-treat (Δ, 1.03%; UL 95% CIΔ, 7.2%; Pnoninferior =.0144) and per-protocol analyses (Δ, 0.83%; UL 95% CIΔ, 7.3%; Pnoninferior =.0157). Major morbidity and 30-day mortality was 12.9% after immediate resection versus 15.4% after mediastinoscopy first (P =.4940).CONCLUSION:On the basis of our chosen noninferiority margin in the rate of unforeseen N2, confirmatory mediastinoscopy after negative systematic endosonography can be omitted in patients with resectable NSCLC and an indication for mediastinal staging.</p

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

WSES Jerusalem guidelines for diagnosis and treatment of acute appendicitis

Acute appendicitis (AA) is among the most common cause of acute abdominal pain. Diagnosis of AA is challenging; a variable combination of clinical signs and symptoms has been used together with laboratory findings in several scoring systems proposed for suggesting the probability of AA and the possible subsequent management pathway. The role of imaging in the diagnosis of AA is still debated, with variable use of US, CT and MRI in different settings worldwide. Up to date, comprehensive clinical guidelines for diagnosis and management of AA have never been issued. In July 2015, during the 3rd World Congress of the WSES, held in Jerusalem (Israel), a panel of experts including an Organizational Committee and Scientific Committee and Scientific Secretariat, participated to a Consensus Conference where eight panelists presented a number of statements developed for each of the eight main questions about diagnosis and management of AA. The statements were then voted, eventually modified and finally approved by the participants to The Consensus Conference and lately by the board of co-authors. The current paper is reporting the definitive Guidelines Statements on each of the following topics: 1) Diagnostic efficiency of clinical scoring systems, 2) Role of Imaging, 3) Non-operative treatment for uncomplicated appendicitis, 4) Timing of appendectomy and in-hospital delay, 5) Surgical treatment 6) Scoring systems for intra-operative grading of appendicitis and their clinical usefulness 7) Non-surgical treatment for complicated appendicitis: abscess or phlegmon 8) Pre-operative and post-operative antibiotics.Peer reviewe

Clinical staging of NSCLC: Current evidence and implications for adjuvant chemotherapy

Survival of all non-small cell lung cancer (NSCLC) patients is disappointing, with a 5-year survival of 18%. Staging NSCLC patients is crucial because it determines the choice of treatment and prognosis. Clinical staging is a complex process that comes with many challenges and with low accuracy between the clinical and pathological stage. Treatment modalities for stage I-III NSCLC consist of surgical resection, radiotherapy and chemotherapy. This review describes the current evidence on staging and the implications on adjuvant chemotherapy. For stage I disease, staging is most accurate. Primary treatment consists of surgery or stereotactic ablative radiotherapy. When a patient has stage II disease, staging is less accurate because more diagnostic modalities are necessary to stage the mediastinal lymph nodes. Surgery remains the primary treatment modality and platinum-based adjuvant chemotherapy gives a 4% 5-year survival benefit. Staging patients with stage III disease is difficult because of the heterogeneity of the patients. It should be decided if a patient has potentially resectable disease with or without risk of incomplete resection. Induction therapy with chemo(radio)therapy followed by surgical resection or definitive chemoradiotherapy are the treatments of choice. The 5-year survival can reach 44% in selected patients. Decisions in staging and treating patients with NSCLC should be made by a multidisciplinary team with sufficient expertise in all aspects of staging and treatment